Hydrochlorothiazide use and the risk of skin cancer (Q19-05)

Hydrochlorothiazide use and the risk of skin cancer (Q19-05)

Q19-05

Overview

Background
  • Hydrochlorothiazide (HCTZ), a thiazide diuretic, is among the most widely used antihypertensive drugs.
  • HCTZ has been shown to have photosensitizing properties and recent observational studies have associated its use with an increased risk of non-melanoma and melanoma skin cancer.
Aims of the study
  • The study objective is to determine whether the use of HCTZ is associated with an increased risk of non-melanoma and melanoma skin cancer compared with the use of angiotensin-converting enzyme (ACE) inhibitors and calcium channel blockers (CCB).

Manuscripts

Presentations

Project Team

Project Lead
Laurent Azoulay PhD
Methods Lead
Robert W. Platt PhD
Content Expert
James Brophy MD, PhD
Steering Committee Liaison
Michael Paterson MSc
Lead Analyst
Matthew Dahl BSc
Staff Scientist
Wusiman Aibibula PhD
Research Assistant
Audray St-Jean MSc
Site Investigator
Jacqueline Quail PhD
Saskatchewan
Site Investigator
Jacques LeLorier MD, MSc, FRCPC, FISPE
Quebec
Site Investigator
Michael Paterson MSc
Ontario
Site Investigator
Hala Tamim PhD
Atlantic
Site Investigator
Laura Dysart Postdoc Fellow
Atlantic
Site Investigator
Greg Carney BSc, PhD
MarketScan
Site Investigator
Sherif Eltonsy MSc, PhD
Manitoba
Site Investigator
Greg Carney BSc, PhD
British Columbia
Site Investigator
Lauren Bresee PhD
Alberta
Analyst
Shan Jin MSc
Saskatchewan
Analyst
Anjie Huang
Ontario
Analyst
David Stock PhD
Atlantic
Analyst
Yan Wang MSc
Atlantic
Analyst
Jason Kim MPH, BHSc
MarketScan
Analyst
Matthew Dahl BSc
Manitoba
Analyst
Nicole Croteau P.Stat
British Columbia
Analyst
Jianguo (James) Zhang MSc
Alberta